NovaBay Historical Income Statement
| NBY Stock | USD 0.09 0.0004 0.45% |
Historical analysis of NovaBay Pharmaceuticals income statement accounts such as Total Operating Expenses of 15 M can show how well NovaBay Pharmaceuticals performed in making a profits. Evaluating NovaBay Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of NovaBay Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining NovaBay Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NovaBay Pharmaceuticals is a good buy for the upcoming year.
NovaBay |
About NovaBay Income Statement Analysis
NovaBay Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to NovaBay Pharmaceuticals shareholders. The income statement also shows NovaBay investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
NovaBay Pharmaceuticals Income Statement Chart
NovaBay Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting NovaBay's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of NovaBay Pharmaceuticals revenue and expense. NovaBay Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, NovaBay Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 15 M in 2024, despite the fact that Interest Expense is likely to grow to (3.3 M). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of NovaBay Pharmaceuticals. It is also known as NovaBay Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from NovaBay Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 15 M in 2024, despite the fact that Interest Expense is likely to grow to (3.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6M | 7.8M | 7.9M | 8.1M | Total Revenue | 8.4M | 14.4M | 14.7M | 10.0M |
NovaBay Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
NovaBay Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NovaBay Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (1.1M) | 5.3M | (4.5M) | 3.1M | 203K | 351.0K | |
| Interest Expense | 1.1M | (129.2K) | 3.0M | (3.8M) | (3.4M) | (3.3M) | |
| Other Operating Expenses | 16.0M | 16.4M | 17.3M | 22.1M | 19.7M | 16.9M | |
| Operating Income | (9.4M) | (6.4M) | (8.9M) | (7.7M) | (5.0M) | (5.3M) | |
| Ebit | (9.4M) | (6.4M) | (8.9M) | (7.7M) | (5.0M) | (5.3M) | |
| Research Development | 184K | 285K | 44K | 174K | 68K | 64.6K | |
| Ebitda | (10.5M) | (1.2M) | (13.4M) | (4.5M) | (4.8M) | (5.0M) | |
| Total Operating Expenses | 14.3M | 12.4M | 14.5M | 15.5M | 12.9M | 15.0M | |
| Income Before Tax | (9.7M) | (11.0M) | (5.8M) | (10.6M) | (9.6M) | (10.1M) | |
| Total Other Income Expense Net | (252K) | (4.6M) | 3.0M | (2.9M) | (4.6M) | (4.4M) | |
| Net Income | (10.5M) | (11.0M) | (6.6M) | (16.3M) | (9.6M) | (10.1M) | |
| Income Tax Expense | 6K | 5K | (4.6M) | (3.8M) | (3.4M) | (3.3M) | |
| Selling General Administrative | 5.3M | 5.9M | 7.2M | 7.5M | 6.3M | 7.5M | |
| Total Revenue | 6.6M | 9.9M | 8.4M | 14.4M | 14.7M | 10.0M | |
| Gross Profit | 4.9M | 6.0M | 5.6M | 7.8M | 7.9M | 8.1M | |
| Cost Of Revenue | 1.7M | 4.0M | 2.8M | 6.6M | 6.8M | 4.7M | |
| Net Income Applicable To Common Shares | (10.5M) | (11.0M) | (6.6M) | (16.3M) | (14.6M) | (15.4M) | |
| Net Income From Continuing Ops | (9.7M) | (11.0M) | (5.8M) | (10.6M) | (13.7M) | (14.4M) | |
| Non Operating Income Net Other | (89K) | 1.3M | (252K) | (4.6M) | (4.1M) | (3.9M) | |
| Selling And Marketing Expenses | 8.8M | 6.2M | 7.2M | 7.8M | 6.5M | 7.0M | |
| Interest Income | 1.2M | 5.2M | 4.6M | 4.1M | 4.7M | 2.9M | |
| Reconciled Depreciation | 65K | 51K | 119K | 483K | 276K | 212.9K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NovaBay Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NovaBay Pharmaceuticals' short interest history, or implied volatility extrapolated from NovaBay Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for NovaBay Stock analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.96) | Revenue Per Share 3.494 | Quarterly Revenue Growth 0.023 | Return On Assets (0.25) | Return On Equity (1.39) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.